00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
21:10 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

FDA approves Bayer’s PI3K inhibitor for follicular lymphoma

FDA granted accelerated approval to an NDA from Bayer AG (Xetra:BAYN) for Aliqopa copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer told BioCentury Aliqopa will be available immediately...
22:23 , Sep 14, 2017 |  BC Extra  |  Company News

FDA approves Bayer’s PI3K inhibitor for follicular lymphoma

FDA granted accelerated approval to an NDA from Bayer AG (Xetra:BAYN) for Aliqopa copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer told BioCentury Aliqopa will be available immediately...
20:44 , Jun 15, 2017 |  BC Week In Review  |  Clinical News

Bayer reports Phase II data for PI3K inhibitor copanlisib in DLBCL

Bayer AG (Xetra:BAYN) reported data from a Phase II trial in 67 patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who received ≥1 prior therapy showing that 60 mg IV copanlisib (BAY...
16:00 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest jointly inhibiting PI3K and either PIM2, TACC1, ZAK, ZFR or ZNF565 could help treat breast cancer. An shRNA screen in a human breast cancer cell line treated...
00:20 , May 19, 2017 |  BC Week In Review  |  Clinical News

Priority Review for Bayer's PI3K in follicular lymphoma

FDA accepted and granted Priority Review to an NDA from Bayer AG (Xetra:BAYN) for copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer expects a decision within six months....
19:31 , May 17, 2017 |  BC Extra  |  Company News

Priority Review for Bayer's PI3K in follicular lymphoma

FDA accepted and granted Priority Review to an NDA from Bayer AG (Xetra:BAYN) for copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer did not respond to an inquiry...
19:41 , Apr 14, 2017 |  BC Week In Review  |  Clinical News

Copanlisib: Ph II CHRONOS-1 data

Bayer said the open-label, international Phase II CHRONOS-1 trial in 142 patients with relapsed or refractory indolent B cell NHL who received ≥2 prior therapies showed that 60 mg IV copanlisib on days 1, 8...
07:00 , Aug 28, 2014 |  BC Innovations  |  Cover Story

Overcoming ibrutinib resistance

Imbruvica ibrutinib's unprecedented response rate in mantle cell lymphoma is generating excitement around the new drug, but as with many targeted cancer therapies, tumors can ultimately become resistant. A recent study from Weill Cornell Medical...